晚期宫颈癌全身治疗模式的转变
Changing paradigms in the systemic treatment of advanced cervical cancer.
作者信息
Pfaendler Krista S, Tewari Krishnansu S
机构信息
Division of Gynecologic Oncology, University of California, Irvine, Orange, CA.
Division of Gynecologic Oncology, University of California, Irvine, Orange, CA; Division of Gynecologic Oncology, University of California, Irvine, Irvine Medical Center, University of California, Orange, CA.
出版信息
Am J Obstet Gynecol. 2016 Jan;214(1):22-30. doi: 10.1016/j.ajog.2015.07.022. Epub 2015 Jul 26.
Despite availability of primary and secondary prevention measures, cervical cancer persists as one of the most common cancers among women around the world. Although early-stage disease can be cured with radical and even fertility-sparing surgery, patients with metastatic and recurrent cervical cancer have poor prognosis with historically limited treatment options and incurable disease. Significant advances in cervical cancer treatment have emerged as the result of clinical trials that have sought to determine the best therapy to prolong overall and progression-free survival. Most recently, trials that have involved angiogenesis blockade in addition to standard chemotherapy have demonstrated improved overall and progression-free survival. This review serves to highlight pivotal trials in chemotherapy development for advanced, metastatic, and recurrent cervical cancer that includes the paradigm-shifting work that demonstrates increased overall survival with angiogenesis blockade.
尽管有一级和二级预防措施，但宫颈癌仍是全球女性中最常见的癌症之一。虽然早期疾病可以通过根治性甚至保留生育功能的手术治愈，但转移性和复发性宫颈癌患者的预后较差，历来治疗选择有限且疾病无法治愈。宫颈癌治疗取得了重大进展，这是临床试验的结果，这些试验旨在确定延长总生存期和无进展生存期的最佳疗法。最近，除标准化疗外还涉及血管生成阻断的试验已证明总生存期和无进展生存期有所改善。本综述旨在强调晚期、转移性和复发性宫颈癌化疗发展中的关键试验，其中包括显示血管生成阻断可提高总生存期的范式转变性研究。
Zotero 插件